Literature DB >> 33044859

Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".

Dhruv S Kazi1,2,3, Brandon K Bellows4, John A Spertus5,6, Suzanne J Baron1,7, Changyu Shen1,2,3, David J Cohen6, Robert W Yeh1,2,3, Suzanne V Arnold6,7, Brett W Sperry6,7, Mathew S Maurer4, Sanjiv J Shah8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33044859      PMCID: PMC8170666          DOI: 10.1161/CIRCULATIONAHA.120.049842

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   39.918


× No keyword cloud information.
  4 in total

1.  Reforming the Orphan Drug Act for the 21st Century.

Authors:  Ameet Sarpatwari; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2019-07-11       Impact factor: 91.245

2.  QALYs in 2018-Advantages and Concerns.

Authors:  Peter J Neumann; Joshua T Cohen
Journal:  JAMA       Date:  2018-06-26       Impact factor: 56.272

Review 3.  The economics of heart failure.

Authors:  Dhruv S Kazi; Daniel B Mark
Journal:  Heart Fail Clin       Date:  2013-01       Impact factor: 3.179

4.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.